Global CMO & CDMO 麻豆原创 Research Report 2023

Publication ID:

PB503248161

Publication Date:

March 8, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

At a time when pharmaceutical companies face increasing price pressures around the globe from key payers, including public and government insurance systems, reducing operational expenses is a major driver of outsourcing pharmaceutical manufacturing to CDMOs. Also, an increasing number of pharmaceutical companies are refocusing on their core capabilities and strengths, leading to divestments of in-house manufacturing capacities in some areas and to a gro
Highlights
The global CMO & CDMO market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for CMO & CDMO is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for CMO & CDMO is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for CMO & CDMO in Pharmaceutical Industry is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of CMO & CDMO include Recipharm, AMRI3, Patheon, Aenova, Catalent, Amatsigroup, WuXi PharmaTech, Strides Shasun and Piramal, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CMO & CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CMO & CDMO.
The CMO & CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CMO & CDMO market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CMO & CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Recipharm
AMRI3
Patheon
Aenova
Catalent
Amatsigroup
WuXi PharmaTech
Strides Shasun
Piramal
Siegfried
Segment by Type
Development
API production
Formulation
Segment by Application
Pharmaceutical Industry
Biotechnology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CMO & CDMO companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global CMO & CDMO 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Development
1.2.3 API production
1.2.4 Formulation
1.3 麻豆原创 by Application
1.3.1 Global CMO & CDMO 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CMO & CDMO 麻豆原创 Perspective (2018-2029)
2.2 CMO & CDMO Growth Trends by Region
2.2.1 Global CMO & CDMO 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 CMO & CDMO Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 CMO & CDMO Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 CMO & CDMO 麻豆原创 Dynamics
2.3.1 CMO & CDMO Industry Trends
2.3.2 CMO & CDMO 麻豆原创 Drivers
2.3.3 CMO & CDMO 麻豆原创 Challenges
2.3.4 CMO & CDMO 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top CMO & CDMO Players by Revenue
3.1.1 Global Top CMO & CDMO Players by Revenue (2018-2023)
3.1.2 Global CMO & CDMO Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global CMO & CDMO 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CMO & CDMO Revenue
3.4 Global CMO & CDMO 麻豆原创 Concentration Ratio
3.4.1 Global CMO & CDMO 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CMO & CDMO Revenue in 2022
3.5 CMO & CDMO Key Players Head office and Area Served
3.6 Key Players CMO & CDMO Product Solution and Service
3.7 Date of Enter into CMO & CDMO 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 CMO & CDMO Breakdown Data by Type
4.1 Global CMO & CDMO Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global CMO & CDMO Forecasted 麻豆原创 Size by Type (2024-2029)
5 CMO & CDMO Breakdown Data by Application
5.1 Global CMO & CDMO Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global CMO & CDMO Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America CMO & CDMO 麻豆原创 Size (2018-2029)
6.2 North America CMO & CDMO 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CMO & CDMO 麻豆原创 Size by Country (2018-2023)
6.4 North America CMO & CDMO 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CMO & CDMO 麻豆原创 Size (2018-2029)
7.2 Europe CMO & CDMO 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CMO & CDMO 麻豆原创 Size by Country (2018-2023)
7.4 Europe CMO & CDMO 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CMO & CDMO 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific CMO & CDMO 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CMO & CDMO 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific CMO & CDMO 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CMO & CDMO 麻豆原创 Size (2018-2029)
9.2 Latin America CMO & CDMO 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CMO & CDMO 麻豆原创 Size by Country (2018-2023)
9.4 Latin America CMO & CDMO 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CMO & CDMO 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa CMO & CDMO 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CMO & CDMO 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa CMO & CDMO 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm
11.1.1 Recipharm Company Detail
11.1.2 Recipharm Business Overview
11.1.3 Recipharm CMO & CDMO Introduction
11.1.4 Recipharm Revenue in CMO & CDMO Business (2018-2023)
11.1.5 Recipharm Recent Development
11.2 AMRI3
11.2.1 AMRI3 Company Detail
11.2.2 AMRI3 Business Overview
11.2.3 AMRI3 CMO & CDMO Introduction
11.2.4 AMRI3 Revenue in CMO & CDMO Business (2018-2023)
11.2.5 AMRI3 Recent Development
11.3 Patheon
11.3.1 Patheon Company Detail
11.3.2 Patheon Business Overview
11.3.3 Patheon CMO & CDMO Introduction
11.3.4 Patheon Revenue in CMO & CDMO Business (2018-2023)
11.3.5 Patheon Recent Development
11.4 Aenova
11.4.1 Aenova Company Detail
11.4.2 Aenova Business Overview
11.4.3 Aenova CMO & CDMO Introduction
11.4.4 Aenova Revenue in CMO & CDMO Business (2018-2023)
11.4.5 Aenova Recent Development
11.5 Catalent
11.5.1 Catalent Company Detail
11.5.2 Catalent Business Overview
11.5.3 Catalent CMO & CDMO Introduction
11.5.4 Catalent Revenue in CMO & CDMO Business (2018-2023)
11.5.5 Catalent Recent Development
11.6 Amatsigroup
11.6.1 Amatsigroup Company Detail
11.6.2 Amatsigroup Business Overview
11.6.3 Amatsigroup CMO & CDMO Introduction
11.6.4 Amatsigroup Revenue in CMO & CDMO Business (2018-2023)
11.6.5 Amatsigroup Recent Development
11.7 WuXi PharmaTech
11.7.1 WuXi PharmaTech Company Detail
11.7.2 WuXi PharmaTech Business Overview
11.7.3 WuXi PharmaTech CMO & CDMO Introduction
11.7.4 WuXi PharmaTech Revenue in CMO & CDMO Business (2018-2023)
11.7.5 WuXi PharmaTech Recent Development
11.8 Strides Shasun
11.8.1 Strides Shasun Company Detail
11.8.2 Strides Shasun Business Overview
11.8.3 Strides Shasun CMO & CDMO Introduction
11.8.4 Strides Shasun Revenue in CMO & CDMO Business (2018-2023)
11.8.5 Strides Shasun Recent Development
11.9 Piramal
11.9.1 Piramal Company Detail
11.9.2 Piramal Business Overview
11.9.3 Piramal CMO & CDMO Introduction
11.9.4 Piramal Revenue in CMO & CDMO Business (2018-2023)
11.9.5 Piramal Recent Development
11.10 Siegfried
11.10.1 Siegfried Company Detail
11.10.2 Siegfried Business Overview
11.10.3 Siegfried CMO & CDMO Introduction
11.10.4 Siegfried Revenue in CMO & CDMO Business (2018-2023)
11.10.5 Siegfried Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Recipharm
AMRI3
Patheon
Aenova
Catalent
Amatsigroup
WuXi PharmaTech
Strides Shasun
Piramal
Siegfried

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.